The present research is an approach to develop a formulation platform that shall help in minimizing the time and effort taken to develop a drug delivery system. Taking bilayer tablet technology as a representation for drug delivery system, well accepted an tihypertensive drugs, Amlodipine besylate and Metoprolol succinate were considered as model drugs for the study. Initially the process variables like concentr ation of the disintegrants, Sodium starch Glycolate and cross carmellose sodium, Polymers HPMC K100M and K4M were standardized with these drugs so that the incorporation of a new combination drugs would provide predictable results with a minimal trial runs. Nebivolol hydrochlo ride and Valsartan were considered as test drugs since they are novel antihypertensive drug combination and their physicochemical and pharmacokinetic parameters were almost similar to that of the model drugs. The r value 0.98943 indicates a good correlation between the release profile of Amlodipine besylate (model drug) and Nebivolol hydrochloride (test drug) from the IR layer. Similarly, the r value in the range of 0.9998 indicates a good correlation between the release profile of Metoprolol succinate (model drug) and Valsartan (test drug) from the SR layer. The comparable experimental results of the model drugs and test drugs considered for this study infer that if two drugs are similar in their physicochemical and pharmacokinetic parameters, their behavior with respect to in vitro parameters will be similar provided formulation variables remains constant. This concept could be productive in developing drug delivery system for new drugs for which extensive research and time are major constraints.
INTRODUCTION
Developing a useful drug delivery system is a result of concerned efforts by the scientist of variety of disciplines who recognize the need and potential for improving pharmcotherapeutics through the development of novel drug delivery systems. The method by which a drug is delivered can have a significant effect on its efficacy. Some drugs have an optimum concentration range within which maximum benefit is derived, and concentrations above or below this range can be toxic or produce no therapeutic benefit at all. In recent times, many guidelines emphasize that the majority of the hypertensive population will require two or more antihypertensive drugs to achieve the recommended treatment goals. 1 Fixed drug combinations (FDCs) of antihypertensive agents have proven to be efficacious in the treatment of hypertension. The availability of many antihypertensive agents in various classes such as diuretics, calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors, angiotensin receptor blockers, β adrenoceptor blockers are frequently combined in FDCs.
A combination of a calcium channel blocker (CCB) Amlodipine besylate with a β adrenoceptor blocker Metoprolol succinate is advantageous since, their modes of action are different yet their action on blood pressure (BP) is complementary. The β adrenoceptor blocker might regulate any CCB-induced acute reflex increase in sympathetic activity and conversely, the CCB might compensate the peripheral vasospasm and drop in cardiac output caused by the β adrenoceptor blocker; thus, reducing the overall burden of side-effects. This is one key to ensure better long-term compliance with therapy and to more effective long-term BP control. 2 Metoprolol succinate and Amlodipine Besylate are in the market for the past two decades or so. These drugs have been extensively researched in various dimensions for optimal hypertension therapy. Hence they were considered as model drugs to develop bilayer tablets which shall help in developing bilayer tablets of recently approved fixed dose combination of Nebivolol Hydrochloride and Valsartan for hypertension.
MATERIALS AND METHODS
Metoprolol succinate, Amlodipine Besylate, Nebivolol hydrochloride and Valsartan were received as gift samples from Apotex Pharmachem India Pvt. Ltd, Bengaluru, India. The polymers such as Hydroxypropyl Methylcellulose K100M (Methocel K100M premium), K4M (Methocel K4M premium), Dibasic calcium phosphate (anhydrous, FCC), sodium starch glycolate (731713H), croscarmellose sodium(Ac di sol NF), FD&C blue lake, microcrystalline cellulose, silicon dioxide (Aerosil 200) and magnesium stearate (ligamed MF) were obtained from KMS Pharma -Formulation development Healthcare Pvt Ltd, Chennai, India.
The present research was carried out in two phases. The phase I consisted of formulation and evaluation of bilayer tablets of model drugs Amlodipine besylate and Metoprolol succinate for immediate release (IR) and sustained (SR) respectively. The II phase consisted of formulation and evaluation of bilayer tablets of test drugs Nebivolol hydrochloride and Valsartan in IR and SR respectively.
Phase I: Bilayer tablets of Amlodipine besylate and Metoprolol succinate

Selection of excipients
The excipients necessary for formulation was selected based on the relevant information from the literature survey on previous research on the same ideology. The excipients which influence modified release in the bilayer tablets such as superdisintegrants: Sodium Starch Glycolate, Croscarmellose sodium and the percentage of polymers like Hydroxypropyl Methylcellulose K100M, K4M were optimized by reference articles. 3 The selected excipients were subjected for incompatibility studies with the drugs.
The ingredients after sifting, prelubrication and blending was subjected for precompression parameters like excipient compatibility studies, Angle of Repose, Bulk Density, Tapped Density Carr's. Index (%), Hausner's Ratio. 4 (Table 1) the Fourier-transform infrared spectroscopy (FTIR) studies were done for standard Amlodipine Besylate, Metoprolol succinate and Excipients. 
Formulation of Bi-layer tablets:
Bi-layer tablets of extended release Metoprolol succinate and immediate release Amlodipine Besylate were prepared through direct compression method according to the composition shown in Table 2 . Various step like sifting, dry mixing, prelubrication and lubrication was carried out prior direct compression process.
Preparation of Amlodipine Besylate immediate release (IR) layer:
Amlodipine Besylate immediate release tablets were prepared by using direct compression method. The microcrystalline cellulose, Dicalcium phosphate, Pregelatinised starch, sodium starch gluconate and the active ingredient were passed through sieve no. 30 and mixed homogenously. Magnesium stearate and Aerosil were passed through sieve no.60 and added as a lubricant to the above dry mix and mixed well for 5 minutes. Finally the colorant FD &C blue lake was sieved through sieve no.100 mesh and then mixed with the dry mix homogenously to get uniform blend without mottling.
Preparation of Metoprolol sustained release (SR) layer:
The active ingredient Metoprolol succinate, was passed through the 40 mesh sieve followed by the other ingredients. Metoprolol succinate, Polymer [Hydroxypropyl Methylcellulose K100M (Methocel K100M premium), K4M (Methocel K4M premium)] diluents [Dibasic calcium Phosphate (anhydrous, FCC)] were taken in a planetary mixer and mixed for 15 minutes to ensure uniform mixing of the ingredients with the drug.Colloidal slicondioxide (Aerosil-200), sifted through 40 mesh sieve were mixed with dry mixed blend for 5 minutes. 5
Tablet compression:
The Bi-layer tablet compression was made using 14/6mm punches in Rimek minicompressor II DL. In this, sustained release Metoprolol Succinate powder were introduced first in to the die cavity and a slight precompression was made so that the layer was uniformly distributed. After that immediate release Amlodipine Besylate granules were added through the other feed and a final compression was made with view to maintain the fixed hardness and uniform weight. 28. 75 57. 5
28. 75 57. 5
28 
In vitro dissolution study 6
Drug Release Studies for Immediate release (IR) layer
The in vitro dissolution of immediate release layer was determined using USP XXIII (basket method) dissolution apparatus. The basket was allowed to rotate at a speed of 100 rpm and temperature of 37 ± 0.5°C was maintained. The dissolution medium used was 900 ml of 0.1N HCl (pH 1.2) for 2 hours. Aliquots (5 ml) of sample were collected at 30 min from the dissolution apparatus and it was replaced with equal volume of fresh dissolution medium. The aliquots withdrawn were filtered through 0.45µm millipore filters. The concentration of Amlodipine in the dissolution media was estimated by HPLC method at 239 nm.
Drug Release Studies for Metoprolol Succinate sustained release (SR) layer 7
The in vitro dissolution of sustained release layer was determined using USP XXIII (basket method) dissolution apparatus. The basket was allowed to rotate at a speed of 100 rpm and temperature of 37 ± 0.5°C was maintained. The dissolution medium used was 900 ml of 0.1N HCl (pH 1.2) for the initial 2hours followed by study in simulated intestinal fluid Phosphate buffer solution (pH 6.8). Aliquots (5 ml) of ISSN: 2250-1177
[532] CODEN (USA): JDDTAO sample were collected at predetermined time intervals (1, 4, 8, 20 hrs) from the dissolution apparatus and it was replaced with equal volume of fresh dissolution medium. The aliquots withdrawn were filtered through 0.45µm millipore filters. The concentration of Metoprolol in the dissolution media was estimated by HPLC method at 280 nm.
Drug Release Studies for Bi-layer Tablets
The in vitro dissolution of Amlodipine and Metoprolol Bi-layer tablets were determined using USP XXIII (basket method) dissolution apparatus. The basket was allowed to rotate at a speed of 100 rpm and temperature of 37 ± 0.5°C was maintained. The dissolution medium used was 900 ml of 0.1N HCl (pH 1.2) for the initial 2hours followed by study in simulated intestinal fluid Phosphate buffer solution (pH 6.8). Aliquots (5 ml) of sample were collected at predetermined time intervals (1, 4, 8, 20 hrs) from the dissolution apparatus and it was replaced with equal volume of fresh dissolution medium. The aliquots withdrawn were filtered through 0.45µm millipore filters. The concentration of both the drugs in the dissolution media was estimated by HPLC method at 239 nm and 280nm for Amlodipine and Metoprolol respectively. 
Interpretation of the kinetic studies:
 The r value for zero order release indicates the SR layer containing valsartan follows zero order release pattern where in the drug release at any moment is independent of the initial concentration.

The r value for Higuchi model infers the SR layer follows a drug release by diffusion process based on Fickian law of diffusion.
The r value for Peppas model shows moderate linearity.
Phase II: Bilayer tablets of Nebivolol Hydrochloride and Valsartan
In the best formulation selected from Phase I experiments, Amlodipine besylate was replaced with Nebivolol hydrochloride and Metoprolol succinate was replaced with
Valsartan. These drugs were considered as main drugs since the combination is novel and has many therapeutic benefits. 9
Rationale for drug selection
Recently, fixed dose combination of Nebivolol hydrochloride, a selective β1 antagonist and valsartan an angiotensin II receptor blocker was approved by USFDA for hypertension. Pharmacological profiles of Nebivolol hydrochloride and valsartan alone and in combination are well characterized. In addition, a large 8-week randomized trial in stages I-II hypertensive patients (N=4161) demonstrated greater blood pressure-reducing efficacy for 33Neb/valsartan SPCs than component monotherapies with comparable tolerability. In a biomarkers sub study (N=805), Nebivolol/valsartan single-pill combination prevented valsartan-induced increases in plasma renin, and a greater reduction in plasma aldosterone was observed with the highest single-pill combination dose vs. valsartan 320 mg/day. 10 Nebivolol, a new anti-hypertensive drug with peripheral vasodilating properties and adrenoceptor antagonism, given in monotherapy, is as effective as amlodipine in reducing clinical BP in elderly patients with essential hypertension, but it is better tolerated and has the additional advantage of reducing sympathetic discharge. Nebivolol may therefore be recommended as a first-line treatment option for the management of elderly patients with mild to moderate uncomplicated essential hypertension. 11 Valsartan is an angiotensin II receptor antagonist that is used in the treatment of hypertension. It act by blocking the binding of angiotensin II and I to its receptors thereby blocking vasoconstrictor and aldosterone secreting effect of angiotensin II selectively. The most preferred route for this drug is oral delivery in the form of tablets. Valsartan has poor water solubility, low bioavailability (approximately 20-25%) and short half-life (nearly hrs.) which makes it an ideal candidate for sustained release. Hence in the present work this ideology is adopted. 12 A comparative physicochemical properties of the four drugs in study has been summarized in 
Formulation of Bi-layer tablets:
The ingredients after sifting, Prelubrication and blending was subjected for precompression parameters like excipient compatibility studies, Angle of Repose, Bulk Density, Tapped Density Carr's. Index (%), Hausner's Ratio. 20 The results are shown in table 9 and 10. The studies were done for standard Nebivolol HCl, Valsartan and Excipients. Six formulations of bilayer tablets were prepared with the variation of excipients as mentioned Table 11 . Various steps (Sifting, Dry mixing, Prelubrication and Lubrication) involved in direct compression process. The formulation procedure was same as the formulation of model drugs. The compressed tablets were analyzed for post compression parameters. The details of the results are shown in Table 12 . 
In vitro dissolution study
All parameters, conditions and procedure for the study was similar to the phase I dissolution studies. 
RESULTS AND DISCUSSION
Different formulations of Bi-layer tablets were prepared and evaluated with an idea to develop Metoprolol Succinate and Amlodipine Besylate as model drugs to be incorporated in sustained release layer and as an immediate release layer respectively. This idea will help in improving hypertension therapy of two drugs and patient's compliance. These two drugs are extensively researched in various formulations for the past two decades. Hence they were considered as model drugs for the present study.
Direct compression method was selected for the formulation. The polymers and other excipients were selected based on the literature survey and satisfying results produced during drugexcipients compatibility studies to develop the final formulation (Table.1 ). In Phase I experiments, bulk density in the range of 0.3 -0.6 gm/cm 3 indicates a good packing characteristics. The Carr's compressibility index was found to be in the range of 37-38 % which suggested optimal compressibility. The values of Hausner ratio where found in the range of 1.5 to 1.6 suggested optimal flowability of powder blend. The angle of repose of all the blend was within range of 27 to 28 indicated excellent flow property of powder blend. The bilayer tablets were evaluated for different physical parameter ( Table 1 ). The hardness of bilayer tablet was found in the range of 10 to 12 kg/cm2 which was more as compared to individual layer because of double compression. The thickness of the bilayer tablet was in the range of 3.5 -3.7 mm which is an excellent value for double layer. The friability was 0.49-0.54% for bilayer tablet which was less than 1 indicating good handling of tablet. The weight variation study showed low standard deviation uniformity in weight of the tablets 300 ± 0.06mg. (Table 3) In Croscarmellose sodium were used in the range of 2 to 4 mg per tablet. The results of drug release from IR layer, infers that at the concentration of 2 to 4 mg both the super disintegrants comply with the limit for drug release in 30 min (Table:5 , fig 1) In the formula for Metoprolol Succinate sustained release layer, Hydroxy Propyl Methyl Cellulose (HPMC K 100 M) and HPMC K4M were used as retardant polymers. From the drug release profile it infers that Hydroxy Propyl Methyl Cellulose (HPMC K 100 M) at a concentration of 50 to 60% produced desired release profile for Metoprolol Succinate extended release layer as per USP limits. F1, F2, F3, F4, F5and F10 were considered best formulations. (Table: 6 , Fig 2&2A) To analyze the pattern of drug release, the drug release data of the best formulations were subjected to release kinetics studies. The results show that formulations depict zero order release pattern where the prime mechanism is diffusion controlled ( Table. 7 ).
For phase II experiment, new combination of antihypertensive drugs, Nebivolol hydrochloride and valsartan were chosen based on the similarities with the model drugs Amlodipine besylate and Metoprolol succinate. In the chosen best formulation F1, F2, F3, F4, F5 and F10 keeping all excipients and their composition same, the model drugs were replaced with the test drugs under consideration. Bilayer tablets were formulated in the similar way and all precompression and post compression parameters analyzed in the same manner. The results are shown in (Table: 9 , 10, and 12). The results are all within limits and nearly similar to the model drugs. The drug release profile of Nebivolol Hydrochloride is shown in ( 3&3A) . Table 15 shows the comparative release profile of Amlodipine besylate and Nebivolol hydrochloride from immediate release (IR) layers. The r value 0.98943 indicates a good correlation between the release profile of Amlodipine besylate and Nebivolol hydrochloride from the IR layer. The bar graph ( Figure 5 ) of the release of these two drugs in 30 minutes indicate that Amlodipine besylate has greater percentage release (96-107%) at 30 minutes than Nebivolol hydrochloride. This may be due to its high solubility profile. In case of Nebivolol extent of release (79 -92%) indicates an improvised solubility since it is a BCS class II drugs. This may be due the superdisintegrants sodium starch glycolate and cross carmellose sodium, which enhances the solubility. Table 16 shows comparative release profile of Metoprolol succinate and Valsartan from sustained release layer (SR). The r value in the range of 0.9998 indicates a good correlation between the release profile of Metoprolol succinate and Valsartan. Figure 6 shows the pattern of release of Valsartan which is almost similar to that of Metoprolol succinate in all formulations. The percentage drug release of Valsartan is less at the consecutive time points when compared to Metoprolol succinate. This might be due to its low solubility profile.
